Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia.
Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia.
复制标题
DOI：
10.1016/j.cmi.2017.08.029
复制
发表时间：
2018-05
期刊：
影响因子：
--
通讯作者：
Di YP
中科院分区：
文献类型：
--
作者：
Chen C;Deslouches B;Montelaro RC;Di YP
P. aeruginosa is a common cause of pneumonia in cystic fibrosis patients with the property to generate multidrug resistance against clinically used antibiotics. Antimicrobial peptides (AMPs) are a diverse group of effector molecules of the innate immunity that protect the host against pathogens. However, the lack of activity in common biological matrices has hampered efforts towards clinical development. In this study, we evaluated the therapeutic potential of engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of P. aeruginosa infection. The human AMP LL37 and WLBU2 were compared for antibiofilm activity using P. aeruginosa on polarized human bronchial epithelial cells; efficacy in P. aeruginosa pneumonia in mice using intra-tracheal (i.t.) instillation of bacteria and AMPs. WLBU2 (16µM) prevents biofilm formation by up to 3-log compared to 1-log reduction by LL37. With a single dose of 1µg (0.05mg/kg) delivered i.t., the initial effect of LL37 was moderate and transitory, as bacterial load and inflammatory cytokines increased at 24h with observed signs of disease such as lethargy and hypothermia (L&H), consistent with moribund state requiring euthanasia. In sharp contrast, WLBU2 reduced bacterial burden (by 2 logs) and bacteria-induced inflammation (leucocytic infiltrates, cytokine and chemokine gene expression) at 6h and 24h post-exposure, with no observed signs of disease or host toxicity. These promising results now establish a much lower minimum therapeutic dose (mTd) of WLBU2 (a net gain of 80-fold) compared to the previously reported 4mg/kg systemic mTd, with significant implications for clinical development.
登录
查看更多内容
影响因子：
5.4
作者：
Travanty, Emily;Zhou, Bin;Wang, Jieru
通讯作者：
Wang, Jieru
影响因子：
3.1
作者：
Speert, DP
通讯作者：
Speert, DP
影响因子：
11.8
作者：
Lipsky, Benjamin A.;Holroyd, Kenneth J.;Zasloff, Michael
通讯作者：
Zasloff, Michael
影响因子：
4.4
作者：
Liu, Yanyan;Di, Marissa E.;Di, Y. Peter
通讯作者：
Di, Y. Peter
影响因子：
5.2
作者：
Lashua, Lauren P.;Melvin, Jeffrey A.;Bomberger, Jennifer M.
通讯作者：
Bomberger, Jennifer M.